AOP Orphan announces European approvable opinion of its ultra-short acting beta blocker Rapibloc®
Ultra-short acting and highly cardio-selective beta blocker Rapibloc® (Landiolol) receives regulatory approval in Europe. Rapibloc® (Landiolol) allows rapid control of heart rate with a straightforward dosing scheme in a variety of perioperative and intensive care situations.
Rapibloc® (Landiolol) will be launched in Europe in the first half of 2017. AOP Orphan Pharmaceuticals AG (AOP Orphan) today announced that it received an “approvable” opinion in the pan-European licensure process of its ultra-short acting beta blocker Rapibloc® (Landiolol). Regulatory approval was received by means of a decentralized procedure involving most European countries.
Because of its short half-life and high cardio-selectivity, Rapibloc® (Landiolol) allows rapid control of heart rate in a variety of perioperative and intensive care situations.
Rapibloc® (Landiolol) will be available as a 20 mg/2 ml concentrate solution for injection, and as powder for solution for infusion in two strengths (300 mg / 600 mg).
“Rapibloc® (Landiolol) is especially suitable for rapid control of heart rate in critically ill patients, its cardio-selectivity and lack of rebound effects after therapy stop, provides physicians with a new tool for highly flexible hemodynamic management. The available formulations include a concentrate which is a unique option for emergency situations, and two dry powder formulations which allow for an easy and straightforward dosing scheme. We believe that the unique clinical, pharmaceutical and practical handling features will bring many advantages of Rapibloc® over existing products”, said Dr. Rudolf Widmann, CEO of AOP Orphan.